Manisha A. Narasimhan | Regeneron Pharmaceuticals, Inc. |
Leonard S. Schleifer | Regeneron Pharmaceuticals, Inc. |
George Damis Yancopoulos | Regeneron Pharmaceuticals, Inc. |
Marion McCourt | Regeneron Pharmaceuticals, Inc. |
Robert E. Landry | Regeneron Pharmaceuticals, Inc. |
Robyn Karnauskas | Citigroup Global Markets, Inc. |
Christopher J. Raymond | Piper Jaffray & Co. |
Ying Huang | Bank of America Merrill Lynch |
Geoffrey C. Porges | Leerink Partners LLC |
Matthew K. Harrison | Morgan Stanley & Co. LLC |
Josh Schimmer | Evercore ISI |
Carter Gould | UBS Securities LLC |
Phil Nadeau | Cowen and Company, LLC |
Cory W. Kasimov | JPMorgan Securities LLC |
Geoff Meacham | Barclays Capital, Inc. |
Matthew Luchini | BMO Capital Markets (United States) |
Brian P. Skorney | Robert W. Baird & Co., Inc. (Broker) |
Jason Jakoby | Goldman Sachs & Co. LLC |
Adnan Butt | Guggenheim Securities LLC |
Welcome to the Regeneron Pharmaceuticals Second Quarter 2018 Earnings Conference Call. My name is Sylvia and I'll be your operator for today's call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Please note that this conference is being recorded.